Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MorphoSys, Schering-Plough Extend Antibody Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

MorphoSys, Schering-Plough Extend Antibody Alliance

MorphoSys AG and Schering-Plough have extended their antibody collaboration for another year.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MorphoSys AG and Schering-Plough have extended their antibody collaboration for another year. The partnership, initiated in May 2006, may be extended by Schering-Plough annually until 2011.

The agreement grants SP continued access to MorphoSys’s antibody library HuCAL GOLD at SP’s research site in Palo Alto, CA, with options for therapeutic licenses. MorphoSys is eligible to receive license fees, plus milestone payments for antibody projects undertaken by SP that advance to clinical development, and royalties on HuCAL antibodies developed under the agreement. Under the extended agreement, MorphoSys continues to receive annual user fees for access to its HuCAL platform.

“We are pleased with Schering-Plough’s decision to extend the current collaboration,” commented Dr. Simon Moroney, chief executive officer of MorphoSys. “This demonstrates once more the continued commitment of leading pharmaceutical companies worldwide to our HuCAL technology for their antibody-based drug development programs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics